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Geographic variation in the aetiology,
epidemiology and microbiology of
bronchiectasis
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and Sanjay H. Chotirmall1*
Abstract
Bronchiectasis is a disease associated with chronic progressive and irreversible dilatation of the bronchi and is
characterised by chronic infection and associated inflammation. The prevalence of bronchiectasis is age-related and
there is some geographical variation in incidence, prevalence and clinical features. Most bronchiectasis is reported
to be idiopathic however post-infectious aetiologies dominate across Asia especially secondary to tuberculosis.
Most focus to date has been on the study of airway bacteria, both as colonisers and causes of exacerbations.
Modern molecular technologies including next generation sequencing (NGS) have become invaluable tools to
identify microorganisms directly from sputum and which are difficult to culture using traditional agar based
methods. These have provided important insight into our understanding of emerging pathogens in the airways of
people with bronchiectasis and the geographical differences that occur. The contribution of the lung microbiome,
its ethnic variation, and subsequent roles in disease progression and response to therapy across geographic regions
warrant further investigation. This review summarises the known geographical differences in the aetiology,
epidemiology and microbiology of bronchiectasis. Further, we highlight the opportunities offered by emerging
molecular technologies such as -omics to further dissect out important ethnic differences in the prognosis and
management of bronchiectasis.
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Background
Bronchiectasis is a major chronic pulmonary disease
characterised by infection, inflammation and a perman-
ent, irreversible dilatation of the bronchial wall. The
interaction of chronic infection, exacerbations and in-
flammation drive a vicious cycle resulting in lung injury
to the bronchi and lung parenchyma. This model pro-
posed by Cole is not well understood in terms of the
underlying biology but includes deficits in mucociliary
clearance and innate and adaptive immunity (Fig. 1).
There is amplification of injury processes following ana-
tomical damage to the bronchi leading to progressive
worsening of pulmonary physiology and symptoms with
associated increase in exacerbations [1]. The host
immune response to infection is primarily neutrophilic
and neutrophil derived proteases are deleterious and re-
sult in further pulmonary damage amplifying a recurrent
cycle [2] (Fig. 1).
Literature search strategy
A PUBMED review of all articles mentioning the key-
word “bronchiectasis” in combination with “epidemi-
ology” or “microbiology” published between 1997 and
2017 was performed. As bronchiectasis in Cystic Fibrosis
(CF) represents a separate disease entity in its own right,
retrieved articles dealing exclusively with CF-associated
bronchiectasis were excluded, as were original articles
without radiological confirmation of bronchiectasis.
Studies of both adult and paediatric populations were
considered and appropriately included.
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Ageing and its impact on bronchiectasis
Bronchiectasis is an age-associated disease [3]. A marked
increase in prevalence, particularly of severe disease is
observed in the elderly [4]. The global shift in ageing will
continue to influence the burden of bronchiectasis, its
disease epidemiology and implications for the healthcare
systems that provide therapy [5]. In many chronic lung
diseases there is an age-related increased prevalence
given the multifactorial impact of the aging process on
respiratory physiology. Physiological change including
decreased diaphragm strength, reduced breathing effi-
ciency and vital capacity (VC) coupled to increases in re-
sidual volume (RV) all have important influences on the
diagnosis and interpretation of pulmonary function test-
ing (PFTs) across a variety of respiratory pathologies as
described by our group and others [6–8]. The dimin-
ution of swallowing reflexes and increased prevalence of
GORD in the elderly may contribute to the development
of bronchiectasis due to subclinical microaspiration in-
cluding the nasopharyngeal microbiota [9]. Elderly
people have more severe disease and atypical presenta-
tion with poorer outcomes compared to younger cohorts
[10]. Age-associated disease manifestations also correlate
closely with variation in immune and microbiome signa-
tures that are associated with the ageing process itself
[11, 12]. The immune system, and potentially the micro-
biome, also undergoes its own change with age, a
process incompletely understood, termed ‘immunose-
nescence’ [13, 14]. Although immunosenescence
influences a variety of respiratory disease states, little is
known about its effects on bronchiectasis [15]. Never-
theless, associations between lung function decline, in-
fection and age suggest that immunosenecence and
potentially bronchiectasis pathogenesis are likely inter-
related [16]. Immunosuppression due to leukaemias and
their treatment are also interestingly associated with
bronchiectasis, a relevant observation for elderly popula-
tions [17]. Age-associated pathways including WNT sig-
nalling, mTOR and Toll-like receptors (TLRs) all have
possible roles in COPD and IPF pathogenesis and could
explain age-associated severity in bronchiectasis. Telo-
mere dysfunction and senescence associated pathways
have been described in explants studied from patients
with bronchiectasis [18]. As such, this represents an im-
portant area of future interest and research [19–21].
Geographic variation in the aetiology of bronchiectasis
Bronchiectasis in children vs adults
A increased risk of non-CF bronchiectasis is observed at
the extremes of age with children under 5 years and
adults over 75 years of age at greatest risk of disease
[22]. Particular aetiologies and clinical manifestations
are observed in childhood bronchiectasis, which more
frequently includes primary and secondary immunodefi-
ciency, ciliary dyskinesia, congenital malformations,
bronchiolitis obliterans and skeletal disease [23]. As with
adult bronchiectasis, infection is highly associated with
disease and those with childhood bronchiectasis are at
Fig. 1 A modern interpretation of Cole’s vicious cycle hypothesis. Abbreviations: NE – Neutrophil elastase, ↑ - Increased
Chandrasekaran et al. BMC Pulmonary Medicine  (2018) 18:83 Page 2 of 14
increased risks of more severe disease in later life [24].
While the most striking incidence of childhood bronchi-
ectasis is seen in indigenous populations including
Maori and Pacific Islanders of New Zealand, Australian
aboriginal and Alaskan native children, increasing rates
have also been observed outside these at risk popula-
tions [25]. It is difficult from the current literature to
discern if the broader global shifts in bronchiectasis
prevalence are due to ‘true’ changes in our understand-
ing of aetiology, including that in childhood or alterna-
tively a better awareness of the disease, a development
of more recent times.
Bronchiectasis in Europe
Cystic fibrosis (CF), caused by dysfunction or absence of
the Cystic Fibrosis Transmembrane Conductor Regula-
tor protein (CFTR) genetically predisposes those affected
to bronchiectasis; but this condition is most prevalent in
Caucasian populations and is less commonly encoun-
tered in Asians. In Europe, North America, Australian
and New Zealand, neonatal screening is widely available
and most people with CF are diagnosed soon after birth.
The majority of non-CF bronchiectasis in studies re-
ported from Europe, Australia and the USA have no
identifiable aetiology and is labelled idiopathic [3, 26].
As infection is crucial in the pathophysiology of bron-
chiectasis, it is unsurprising that post-infection bronchi-
ectasis is the most commonly identifiable cause for
disease development. Infection with Mycobacterium
tuberculosis, non-tuberculosis mycobacteria (NTM),
childhood Bordetella pertussis (whooping cough) and vi-
ruses including influenza, measles and adenovirus, have
all been implicated in post-infection bronchiectasis
states. It is however, in many such cases, difficult to be
certain of this aetiology because of recall bias from
events often many decades in the past. Importantly,
COPD, asthma, connective tissue disease and immuno-
deficiency are all noted as important potential contribut-
ing factors among European patients [3, 27]. Gender
seems to additionally exert an effect on particular aetiol-
ogies with males more likely to exhibit COPD and fe-
males more likely to exhibit asthma-related aetiologies
[3]. European patients with COPD also tended to be
older while immunodeficiency, ciliary dysfunction and
irritable bowel disease (IBD) were all observed in youn-
ger patients [3]. The co-morbidities seen most com-
monly in Europe include COPD, asthma and IBD; all
representing independent mortality risk factors in those
with non-CF bronchiectasis [27]. COPD-associated
bronchiectasis is a leading cause in Europe [3, 28–30]
with allergic reactions to fungi belonging to the genus
Aspergillus (Allergic bronchopulmonary aspergillosis -
ABPA) particularly notable in United Kingdom (UK)
based cohorts [28, 31, 32].
Bronchiectasis in the Americas
Bronchiectasis caused by immune-related mechanisms
including autoimmunity, immunodeficiencies and
hematologic malignancies were identified as predomin-
ant aetiologies in the United States [33]. This work dem-
onstrates a low rate of idiopathic bronchiectasis and
importantly reveals that systematic evaluation may iden-
tify an aetiology in a high proportion of cases suggested
by an earlier UK study [31]. In the US, immune dysfunc-
tion was frequently associated with bronchiectasis in-
cluding that among stem-cell transplant recipients who
suffered graft versus host disease [33]. Outside of indi-
genous Canadian cohorts, where high rates of childhood
bronchiectasis are reported, data on aetiology of adult
Canadian non-CF bronchiectasis is rather limited and
the precise nature of aetiology in this country is largely
uncertain [34, 35]. In Latin America aetiology is, like
elsewhere, driven by infection and influenced by infec-
tious disease epidemiology such as that in endemic TB
regions or against backdrops of higher rates of pertussis
and measles which in turn relate to the lower vaccine
uptake rates. Higher rates of pneumonia and tubercu-
losis in childhood are also likely key contributing factors
to bronchiectasis in this region [36].
Bronchiectasis in the Asia-Pacific region
The true prevalence of bronchiectasis in communities in
the Asia-Pacific region is largely unknown and should be
considered a potential diagnosis in all populations. Im-
portant aetiologies of bronchiectasis seen in other re-
gions including immunodeficiency syndromes such as,
common variable immunodeficiency, secondary im-
munoglobulin disorders (frequently drug related) and
mucociliary defects including primary ciliary dyskinesia,
chronic aspiration, autoimmune/connective tissue dis-
eases, particularly rheumatoid arthritis, and ABPA are
described and in some cases result in a delayed diagno-
ses. In Japan, a less studied inflammatory disease, sino-
bronchial syndrome is documented in many cases of
bronchiectasis [37].
While geographic variation in bronchiectasis aetiology
is described, selection or referral biases, and, the extent
of testing to seek a diagnosis of bronchiectasis in indi-
vidual patients may have resulted in the observed pat-
terns in the populations reported. Figure 2 illustrates the
existing literature of available studies focused on bron-
chiectasis aetiology based on geography.
Geographic variation in the epidemiology of bronchiectasis
Bronchiectasis in children vs adults
The most striking variation in bronchiectasis epidemi-
ology is observed among indigenous children of Australia,
Alaska, Canada and New Zealand [34, 35, 38–40]. Here,
paediatric populations exhibit exceptionally high rates
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compared to non-indigenous groups with infant or child-
hood pneumonia cited as the primary cause in many
cases. These combined observations point to the contribu-
tion of genetic predisposition, early childhood infection
and overall lower socio-economic status as important fea-
tures in pathogenesis particularly among specific indigen-
ous populations [25]. Considering the Pacific region; a
high incidence is observed in children under 15 years of
age in New Zealand and substantial differences noted
within their indigenous ethnic groups and across their
geographic regions [41]. Most paediatric bronchiectasis in
New Zealand is idiopathic with predominant chronic
Haemophilus influenzae infection which in turn associates
with reduced lung function [42]. Bronchiectasis in chil-
dren is also associated with high rates of hospital admis-
sion particularly in Australian aboriginal children. This
latter group have one of the highest reported prevalence
rates of bronchiectasis (14.7 per 1000) worldwide [43, 44].
In separate work, Alaskan native children are described to
have extremely high rates of bronchiectasis compared to
other populations and, in most of these individuals, infant
or childhood pneumonia is the primary cause of disease
[38–40]. All the aforementioned patient groups are clearly
enriched by disease occurrence, an important feature that
offers the opportunity for research to better understand
the roles and interaction of genetic predisposition and
early childhood infection to the subsequent development
of bronchiectasis.
Bronchiectasis in Europe
Incidence and prevalence rates of bronchiectasis in the UK
have increased annually from 2004 and are associated with
significant mortality [4]. Studies from the UK’s North East
(n = 189) illustrate that occurrence of idiopathic bronchi-
ectasis is high and that those identified with post-infective
aetiology developed the condition earlier in life [28]. In
contrast, a Greek study (n = 277) demonstrated that prior
tuberculosis, pertussis, measles and pneumonia were the
leading causes of bronchiectasis [45]. A retrospective study
from Nice in southern France (n = 311) similarly described
high rates of post-infectious (mainly post-tuberculous)
bronchiectasis [29]. Despite these country-based reports, a
large multicentre dataset (n = 1258) collated from across
Europe (Monza, Italy; Dundee and Newcastle, UK; Leuven,
Fig. 2 Predominant aetiologies across different geographic regions and ethnic populations. The individual pie charts indicate the top aetiologies
(top 4 or 5) in each cohort. Abbreviations: ABPA – Allergic Broncho-Pulmonary Aspergillosis, COPD – Chronic Obstructive Pulmonary Disorder,
NTM – Non-Tuberculosis Mycobacteria, GERD – Gastro-Esophageal Reflux Disease
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Belgium; Barcelona, Spain; Athens, Greece and Galway,
Ireland) illustrated that most patients have idiopathic
disease. Among identifiable causes of bronchiectasis, post-
infectious did however remain the commonest.
Interestingly in this large dataset, COPD-related bron-
chiectasis was associated with a higher Bronchiectasis
severity index (BSI) [3].
In Germany (2005–2011) the prevalence of bronchiec-
tasis was 67 cases per 100,000; associated with concomi-
tant increases in hospital admissions and an increased
incidence with age [46, 47]. A large population based
study in Catalonia (north-eastern Spain) similarly found
high prevalence (36.2 cases per 10,000) and incidence
rates (4.81 cases per 10,000). In contrast to other global
datasets, the prevalence and incidence of bronchiectasis
in this study was highest in older males [48]. A larger
multicentre study in Spain however showed contrasting
results with higher prevalence in females and elevated
rates of post-infectious disease [30]. Of interest, greater
hospital admissions and treatment costs per patient in
Spain were inversely related to bronchiectasis where it
was the primary diagnosis but increased when identified
as a secondary diagnosis clearly highlighting a need for
focus on earlier diagnosis [49]. Northern European
countries such as Finland interestingly report a lower in-
cidence of bronchiectasis compared to worldwide esti-
mates. This is also accompanied by lower hospitalisation
and mortality rates from the disease [50, 51]. Overall,
these data clearly illustrate the changing and variation in
epidemiology and aetiology of bronchiectasis even
within Europe which in turn contrasts to that in the
Americas and Asian sub-continents.
Bronchiectasis in the Americas
Seitz et al. (2012) reported an annual increase of 8.7% in
the prevalence of bronchiectasis in the US with a higher
prevalence in Asian Americans when compared to
European and African Americans. This was based on
thoracic computed tomography (CT) scans [52]. Similar
increases in bronchiectasis incidence was described be-
tween 2009 and 2013 with high rates in women and the
elderly [53]. McShane et al. (2012) further illustrated that
ethnicity was one of the major contributing factors for the
observed aetiological differences in disease, an important
consideration for clinicians in an increasingly multi-ethnic
resident population across different countries. Rheuma-
toid Arthritis (RA) was interestingly a common aetiology
in African Americans and hematologic malignancies more
common in European Americans in this study. Subse-
quent work also supports the association between
hematologic malignancy and bronchiectasis while the role
of connective tissue disorders is also corroborated by sev-
eral investigations [17, 54]. The first report from the US
bronchiectasis research registry was recently published
and characterised 1826 patients. Its results concurred with
others and illustrated a higher occurrence in women.
Within the analysed cohort, a higher prevalence of the dis-
ease was described in European Americans [55]. The sta-
tus of bronchiectasis as a largely under-studied disease is
further reflected by the relative lack of prevalence data
from Canada, the Caribbean and South America, where
further studies are warranted.
Bronchiectasis in the Asia-Pacific region
In the Asian subcontinent, considerable gaps in our un-
derstanding of bronchiectasis epidemiology continue to
exist. No comprehensive prevalence datasets for either
China or India are currently available however work is
currently ongoing to address this. There are sporadic re-
gional reports available that provide some insight into
bronchiectasis in this highly affected region.
A recent pan-Indian study (n = 680) identified post-
infection (41%) to be the primary cause for bronchiec-
tasis with post-tuberculous disease identified as the
predominant aetiology (29.8%), whilst ABPA is the most
common cause after this and identified in 12% of Indian
cases [56]. An aetiological study across different ethnicities
in the Guangzhou region of mainland China (n = 148)
identified idiopathic bronchiectasis (45%) as the most
common cause with the high rates of disease related to
post-infection (27%) also noted [57]. Among the Han
population of mainland China (n = 476), rates of idio-
pathic bronchiectasis (66%) are even more striking and
followed by post-tuberculosis as the most prevalent aetiol-
ogies observed (16%) [58].These Chinese studies illustrate
that whilst post-tuberculous bronchiectasis remains im-
portant in Asia, idiopathic bronchiectasis is also highly
prevalent. In a small study from Hong Kong (n = 100),
idiopathic disease dominates (82%) and patients with
bronchiectasis are mainly female with high hospitalisation
and mortality rates; 21.9 cases per 100,000 and 2.7 cases
per 100,000 respectively [59, 60].
In contrast to China however, work from Thailand
(n = 50) indicates that post-infection related bronchi-
ectasis and specifically post-tuberculosis associated
disease was commonest. Similarly, a high prevalence
of post-infectious bronchiectasis was reported in
Indian children (n = 80) followed by primary ciliary
dyskinesia and ABPA [61, 62]. A high prevalence of
bronchiectasis is reported in South Korea (n = 1409)
and in one particular study of respiratory patients, 9%
were deemed to have bronchiectasis with higher
prevalence in females [63].
A variety of reasons may be put forward to explain the
outlined epidemiological differences in bronchiectasis
that exist across Europe, the Americas and the Asia-
Pacific. For example, tuberculosis is rare in more devel-
oped countries when compared to the Asia-Pacific or
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Africa potentially explaining the high frequencies of post-
tuberculous disease found in these regions. Potential gen-
etic predisposition to bronchiectasis may account for the
increased disease prevalence in indigenous communities
in the Asia-Pacific region. The influence of the environ-
ment and its accompanying climate may also influence
microorganisms and/or pathogens that affect the bronchi-
ectasis airway. Hence, we next outline geographic varia-
tions in the airway microbiology in bronchiectasis which
in itself may account for some of the observed differences
in epidemiological patterns of disease.
Geographic variation in the microbiology of bronchiectasis
The Bacteriome
Pseudomonas aeruginosa and H. influenzae are the most
common bacteria detected in bronchiectasis airways glo-
bally although proportions vary among the different
populations [45, 64]. Other bacterial genera described in
bronchiectasis airways include Streptococcus, Prevotella,
Veillonella and Staphylococcus [65–67]. P. aeruginosa is
associated with poorer pulmonary function, higher hos-
pitalisation rates and greater morbidity and mortality
compared to H. influenzae [68–78].
Non-tuberculosis mycobacteria (NTM) are another
important group of organisms that frequently infect the
airway in adult bronchiectasis. Bronchiectasis and NTM
are highly associated pulmonary diseases with airway
distortion predisposing to NTM infection [79, 80].
While NTM is isolated from the bronchiectasis airway
and clearly associates with poorer outcomes and more
aggressive disease in most cases (largely dependent on
the species involved), in some studies, it interestingly
has been associated with a milder phenotype, less se-
vere disease, lower exacerbations and better pulmonary
function [81, 82]. NTM colonisation in common with
P. aeruginosa is more frequent in older patients with
gender preponderance for postmenopausal women and
a lower prevalence is observed in paediatric popula-
tions [82–85]. Mycobacterium avium complex (MAC)
is generally the most common form affecting bronchi-
ectasis patients although geographic variation exists
[80, 82, 84, 86].
The bronchiectasis bacteriome in children vs adults
Studies in children focused on bronchiectasis microbiol-
ogy highlight H. influenzae as the most prevalent sputum
organism (30–83%) from work originating in New
Zealand. Of note, P. aeruginosa largely considered an
airway organism affecting adults was described in up to
4% of children with bronchiectasis with S. pneumo-
niae (5–14%) and M. catarrhalis (2–8%) also de-
scribed [41, 42, 85]. Several studies, some using
bronchoalveolar lavage (BAL) from indigenous chil-
dren in Northern Australia, showed marked similarity
for their microbiology compared to the New Zealand
datasets except that none of the children in this latter
work were P. aeruginosa positive [87, 88]. When
compared to European paediatric data from the UK
and Ireland; children were found to have similar di-
chotomy between H. influenzae and P. aeruginosa in
the airway and also high detection of S. pneumoniae
[89–91]. There are however some notable intra-
country differences in geographic patterns for P. aeru-
ginosa: low levels in Newcastle compared to higher
levels in London (5% versus 11% respectively) which
contrasts to M. catarrhalis where occurrence in
Newcastle is higher than that in London [90, 91].
Such differences may reflect differing referral patterns or
presence of specialist clinics at particular centres but
nonetheless serve to highlight the spectrum of disease het-
erogeneity seen in children. When evaluated against data
from an adult bronchiectasis population in the UK, ex-
pectedly higher rates of P. aeruginosa (49%) are observed
compared to the paediatric cohorts [70]. Taken together,
these observations suggest that variation in paediatric
bronchiectasis microbiology may be more complex than
that in adults and illustrate within-country differences in
addition to geographic and continental variation.
The bronchiectasis bacteriome in Europe
In European studies of the bacteriome in adult bronchi-
ectasis, data combining Spanish and Scottish datasets il-
lustrate equal proportions of H. influenzae and P.
aeruginosa with E.coli interestingly isolated from a tenth
of the studied cohort [92]. Separate work from Greece,
Belgium and France concur with other European studies
detecting high rates of airway P. aeruginosa and H. influ-
enzae but low NTM [29, 45, 47, 93]. An important
study, using 16 s rRNA sequencing from Northern
Ireland showed that change to bacterial communities in
the bronchiectasis airways may not in fact be a driver for
exacerbations however a trend toward lower microbial
diversity was described. In terms of relative abundance,
Haemophilus spp. dominates Pseudomonas spp. in stable
patients and post-antibiotic treatment, a mild increase in
anaerobic bacteria is seen with a corresponding decrease
in aerobes [94]. In contrast however, other 16 s rRNA
datasets assessing both the stable and exacerbation states
found that P. aeruginosa was the commonest organism in
both categories [65]. More recent studies, also from the
UK, have reaffirmed the important original observations
that changes from a stable to exacerbation state involves
more than a simple alteration in the bronchiectasis air-
way bacteriome [67]. While it may be too early to
speculate on specific patterns of microbes and an
association to exacerbations, data in support of this
hypothesis is the observation (from pyrosequencing UK
datasets) that an inverse relationship does exist between
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airway abundance of P. aeruginosa and H. influenzae in
the bronchiectasis airway and that specific microbial
patterns do associate with the exacerbation state [71].
Sequencing approaches have also interestingly shown
that long-term erythromycin treatment adversely affects
H. influenzae-dominant patients by increasing the rela-
tive abundance of P. aeruginosa [66, 95].
The bronchiectasis bacteriome in the Americas
Varying rates of colonisation by P. aeruginosa are
described across varied ethnic groups in the US with His-
panic Americans having the highest rates, followed by
European Americans and African Americans [33]. In
more recent data from the US Bronchiectasis research
registry (n = 1826) however, NTM were found to be most
frequent (54%) with MAC followed by M. abscessus and
M. chelonae being the commonest isolated NTM species.
P. aeruginosa was described in one-third and S. aureus in
one-eighth of patients with colonisation by either of these
species less in patients affected by NTM. Patients with de-
tectable NTM also developed bronchiectasis later and
were predominantly female [55]. Studies from Europe
have found similar discordance between NTM and these
other bacteria in the bronchiectasis airways [96]. Of note,
however, is the ascertainment bias in the US bronchiec-
tasis research registry: many are tertiary referral centres
with NTM referral patterns potentially skewing the re-
ported data. It is likely that the US does however have
more NTM-associated disease overall in comparison to
other geographic regions however the current available
datasets don’t permit us to definitively establish this.
The bronchiectasis bacteriome in the Asia-pacific region
In Asia, similar patterns, in both the ethnic Han popula-
tion from Shandong province (eastern China) and the
southern Chinese city of Guangzhou are observed with
predominance of P. aeruginosa and H. influenzae with
colonisation rates of the former stable across the differ-
ent bronchiectasis aetiologies identified in these popula-
tions. NTM rates unlike the US were low in Chinese
studies [57, 58]. Prospective work from Thailand found
similar patterns to that described in China although in
this population Klebsiella pneumoniae was detected in
equal proportions to H. influenzae [61]. South Korea has a
different distribution with high NTM (44.5%), similar to
that of the US and lower rates of P. aeruginosa (18.1%).
Like the Thai patients, South Koreans also had a signifi-
cant prevalence of K. pneumoniae [97]. While geographic-
ally close; work from Japan however reports P. aeruginosa
as the predominant airway bacteria (24%) closely followed
by only moderate levels of NTM (19%) [37]. Interestingly,
in the Pacific region, specifically central and southern
Australia; reported rates of H. influenzae (36–81%)
compared to P. aeruginosa (7–26%) are higher with very
low occurrences of NTM (1–2%) [88, 98, 99].
A higher mean relative abundance of Haemophilus
spp. compared to Pseudomonas spp. was reported in an
Australian study. The authors propose a bacteriome
based patient stratification system to predict exacerba-
tions in bronchiectasis. In this system, patients with an
airway bacteriome dominated by P. aeruginosa or
Veillonella spp. experience higher rates of future exacer-
bations compared to patients whose airways are domi-
nated by H. influenzae [100]. In addition, H. influenzae
dominant individuals experience milder disease in con-
trast to P. aeruginosa which may be attributed to com-
petitive exclusion between the organisms [101]. While
interesting, these observations are importantly derived
from datasets from the BLESS trial that assessed patients
with a history of at least two exacerbations per year.
Therefore, these identified patterns were based on com-
parisons between ‘very frequent’ to ‘less frequent’ exacer-
bators and lacked assessment against non-exacerbators.
While culture based detection of airway bacteria is rou-
tinely used in bronchiectasis, next-generation sequencing
(NGS) approaches are being used in research as a faster
and more robust alternative for identifying airway patho-
gens [65, 66, 102]. Such culture-independent sequencing
methodologies have been applied in bronchiectasis and
identify a greater degree of airway microbial diversity
(Table 1) [103, 104]. These methods are not yet appropri-
ate for clinical use because of the challenges in bioinfor-
matic analysis and standardisation. This will be efficiently
computerised in the coming years and facilitate clinical
translation. In spite of the increasing exploration of the
bacteriome using such technological advances, exploration
of viral and fungal residents of the lung and their associ-
ation with bronchiectasis has lagged behind. While the
small number of available studies limits our understanding
of viral and fungal contributions to bronchiectasis and
their geographic variability, we nonetheless review below
their currently understood respective contributions and
the evidence supporting their clinical association with
bronchiectasis.
The Virome
Our current understanding of the virome in bronchiec-
tasis is limited and most studies of viruses in bronchiec-
tasis are rarely assessed compared to the baseline
presence of viruses in healthy individuals. Recent work
however has suggested a role for viruses in exacerba-
tions of bronchiectasis where bacterial density and diver-
sity remains stable during exacerbations [94]. Early work
from the US and Canada were the first to report viral in-
fection, specifically Influenza B and adenovirus in bron-
chiectasis, respectively [105, 106]. More recently, work
from China (Guangzhou) reports coronavirus, rhinovirus
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Table 1 Predominant pathogens identified in bronchiectasis cohort studies
Method Population Sample size Predominant
pathogens
(by sequencing)
Predominant
pathogens
(by culture)
Ref
Sputum
culture
BAL
culture
16S rRNA
sequencing
✓ Adult n = 123 N.A. P. aeruginosa
H. influenzae
M. avium intracellulare
S. pneumoniae
S. aureus
[128]
✓ Adult n = 100 N.A. P. aeruginosa
H. influenzae
S. pneumoniae
S. aureus
M. catarrhalis
[74]
✓ Adult n = 193 N.A. H. influenzae
P. aeruginosa
M. catarrhalis
S. pneumoniae
S. aureus
A. fumigatus
[32]
✓ Adult n = 155 N.A. H. influenzae
P. aeruginosa
S. pneumoniae
M. catarrhalis
S. aureus
[70]
✓ ✓ Adult n = 77 N.A. H. influenzae
S. pneumoniae
P. aeruginosa
[129]
✓ Children n = 113 N.A NTHi
S. pneumoniae
M. catarrhalis
S. aureus
P. aeruginosa
[88]
✓ Adult n = 89 N.A. H. influenzae
P. aeruginosa
M. catarrhalis
S. pneumoniae
S. aureus
Aspergillus spp.
M.avium complex
[69]
✓ Adult n = 11 P. aeruginosa
Prevotella spp.
Streptococcus spp.
Haemophilus spp
N.A. [65]
✓ Adult n = 41 H. influenzae
P. aeruginosa
S. pneumoniae
S. aureus
M. catarrhalis
N.A. [66]
✓ ✓ Adult n = 70 Pseudomonadaceae
Pasteurellaceae
Streptococcaceae
P. aeruginosa
H. influenzae
[71]
✓ ✓ Adult Culture:
Stable: n = 40
Exacerbation : n = 11
Sequencing:
Stable: n = 10
Exacerbation : n = 19
Haemophilus spp.
Pseudomonas spp.
Streptococcus spp.
Achromobacter spp
Stable patients:
P. aeruginosa
H. influenzae
Prevotella spp.
Veillonella spp.
Exacerbation patients:
P. aeruginosa
H. influenzae
S. pneumoniae
Methicillin-resistant
S. aureus
[94]
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and influenza A and B detection during exacerbations
which is associated with concomitant increases in both
airway and systemic inflammation (IL-1β; IL-6) [107].
Systemic and airway TNF-α was also elevated in virus
positive exacerbations [107]. Interesting work from
Australian indigenous children similarly illustrates an in-
creased viral detection, particularly rhinoviruses during
exacerbations. Children positive for virus during an ex-
acerbation are also more likely to be hospitalised [108].
These data however do not elucidate whether viruses are
a cause or consequence of exacerbations, an area for fu-
ture investigation. Despite this, recent work from both
Europe and the Asia-Pacific has indicated a potential
role for human T-lymphotropic virus type 1 (HTLV-1)
mediated inflammation in the causation of bronchiec-
tasis [109, 110]. A separate New Zealand based study
similarly proposed adenovirus infection as a potential
cause of post-infectious bronchiectasis (Fig. 3) [111].
The Mycobiome
Our knowledge of the pulmonary mycobiome is less well
characterised and although technically challenging, may
provide new insight into its potential role in bronchiec-
tasis. Fungi, a separate kingdom of organisms with more
Table 1 Predominant pathogens identified in bronchiectasis cohort studies (Continued)
Method Population Sample size Predominant
pathogens
(by sequencing)
Predominant
pathogens
(by culture)
Ref
Sputum
culture
BAL
culture
16S rRNA
sequencing
✓ ✓ Adult Stable n = 76, n = 64/76 patients
followed-up during exacerbation.
Hemophilus spp.
Pseudomonas spp.
Streptococcus spp.
P. aeruginosa
S. aureus
H. influenzae
[67]
The list order of pathogens corresponds to frequency of identification. Abbreviations: P. aeruginosa – Pseudomonas aeruginosa, NTM – Non-Tuberculosis
Mycobacteria, H.influenzae – Haemophilus influenzae, NTHi – Non-typeable Haemophilus influenzae, C. albicans – Candida albicans, S. pneumoniae – Streptococcus
pneumoniae, S. aureus – Staphylococcus aureus, M. catarrhalis – Moraxella catarrhalis, A. fumigatus – Aspergillus fumigatus, M. avium – Mycobacterium avium
Fig. 3 Differences in the microbiome between Europe, the US and the Asia-Pacific by sputum culture illustrating the predominant organisms in stable
states and viruses only during exacerbations. The bacteriome contributes to host inflammation and disease severity, the virome in exacerbations and
the mycobiome is an understudied group with potential clinical impact. Abbreviations: US – United States, UK – United Kingdom, P. aeruginosa –
Pseudomonas aeruginosa, NTM – Non-Tuberculosis Mycobacteria, H.influenzae – Haemophilus influenzae, NTHi – Non-typeable Haemophilus influenzae,
HTLV-1 – Human T-Lymphotropic Virus type 1, C. albicans – Candida albicans, ABPA – Allergic Broncho-Pulmonary Aspergillosis, CPA – Chronic
Pulmonary Aspergillosis, IPA – Invasive Pulmonary Aspergillosis, IA – Invasive Aspergillosis ↑ - Increased, ↓ - Decreased
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than 1.5 million estimated species requires dedicated
study in bronchiectasis where anatomical distortion to
the airways predisposes patients to both acquisition and
colonisation by fungi [103, 112–115]. Those belonging
to the Ascomycota phyla (e.g. Aspergillus spp.) form
spores and through inhalation, on a daily basis, thou-
sands of fungal spores have access to the airways [103].
Dependant on the underlying state of host immunity,
disease can result and, manifestations range from allergic
(in immune hyper-reactivity) to invasive (in severe im-
munodeficiency). Such disease variation is best charac-
terised by Aspergillus-associated syndromes outlined in
Fig. 3. Allergic bronchopulmonary aspergillosis (ABPA)
is a recognised aetiological factor for the occurrence of
bronchiectasis while sensitisation increases the incidence
of bronchiectasis in asthmatics [116–119].
In addition to Aspergillus, Candida spp. represents an-
other fungal genus of potential importance, one rou-
tinely cultured from airway samples. Importantly,
Candida spp. are abundant in the oral cavity even of
healthy individuals and hence whether they represent
genuine respiratory colonisers and/or pathogens in
bronchiectasis remains uncertain [120].
A great paucity of data exist specifically assessing fungi
in the airways of patients with bronchiectasis. Most stud-
ies of bronchiectasis don’t specifically include dedicated
fungal culture and most published reports are based on
their incidental detection. As documented by recently
published ‘research priorities in bronchiectasis’ from the
EMBARC collaboration, work addressing fungi is both ne-
cessary and of importance in bronchiectasis [121]. A
Spanish study reports that Aspergillus and Candida spp.
together contribute the highest proportion of fungi iso-
lated by culture from the bronchiectasis airway. Within
the Aspergillus genus, A. fumigatus is the most common
coloniser and other filamentous fungi such as Penicillium,
Scedosporium and Fusarium are less frequently seen. Crit-
ically, chronic antibiotic use in this work was associated
with prolonged colonisation by these fungi [82]. Data from
the US bronchiectasis research registry (n = 1826) reports
an incidence of 19% of Aspergillus spp. in their population
[55] Two separate studies from the UK illustrate that A.
fumigatus colonisation and/or sensitisation is positively
correlated with NTM occurrence. The co-existence of
chronic pulmonary aspergillosis and NTM infection pre-
dicts mortality in bronchiectasis [122, 123]. Culture-based
identification, part of the routine diagnostic microbiology
work up in bronchiectasis is inefficient for fungal detec-
tion because most fungal species do not grow on common
laboratory media [124]. To overcome this, work employ-
ing next-generation sequencing (NGS) such as targeted
amplicon sequencing and whole-genome shotgun metage-
nomics may reveal the true diversity of fungal microor-
ganisms within the microbiome that may colonise and
contribute to pulmonary pathology in bronchiectasis and
as such should be a focus for future work [103, 104, 125].
Figure 3 summarises the ‘microbiome’ in bronchiectasis
that consists of the ‘bacteriome’, ‘virome’ and ‘mycobiome’
where based on country, the predominant organism has
been identified and geographical differences outlined be-
tween Europe, the US and the Asia-Pacific. Findings relat-
ing to adult and paediatric populations are also indicated.
Geographic variation in clinical bronchiectasis phenotypes
Studies assessing clinical phenotypes in bronchiectasis
are lacking. The most extensive study to date included
1145 patients across five databases in Europe and identi-
fied four distinct phenotypes: severe Pseudomonas infec-
tion (16%), other chronic infections (24%), daily sputum
production without colonisation (33%) and dry bronchi-
ectasis (27%) [126]. This contrasted with a single re-
ported Asian analysis from China where 148 patients
were assessed [127]. Again, four different groups were
identified but the only commonality was a severe group
with post-infective bronchiectasis and the presence of
airway Pseudomonas. Other key groups from the
Chinese study included mild idiopathic disease in young
patients, severe idiopathic disease of late-onset and
moderate disease in the elderly. A third study focused
solely on the Spanish national database of 468 patients
again identified the presence of airway Pseudomonas as
a separate clinical phenotype [30]. In this setting, it was
characterised by severe disease, chronic infection, airflow
obstruction and severe exacerbations in elderly men.
Geographic variation in bronchiectasis phenotypes is
likely very relevant for our understanding of disease
pathogenesis according to region and requires further
and more detailed study. Importantly, while results from
the various cluster studies in bronchiectasis may repre-
sent true geographic variation in disease, they are limited
by the quality and quantity of data put into the cluster-
ing process itself and, has largely remained uncontrolled
for referral bias. An overwhelming message across all
three studies is that clinical data alone was poor at iden-
tifying meaningful patient ‘clusters’ providing a strong
argument for alternative approaches including use of
“omics” for patient stratification. Perhaps targeted thera-
peutic approaches in the future, applicable to specific re-
gions and populations may become relevant as we start
to decipher the drivers of varying endotypes of disease.
Conclusion
As the incidence and prevalence rates of bronchiectasis
continue to increase with global ageing, it can no longer
be considered an ‘orphan’ respiratory disease. Despite its
documented economic burden, effects on quality of life,
and social implications, bronchiectasis is a relatively
neglected pulmonary disease. Further investment and
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research are now required, that which focuses on ethnic
variations and accounts for geographical differences to
permit a more ‘personalised’ approach to its diagnosis,
management and understanding of prognosis across
countries. The recommendations for research priorities
in bronchiectasis by the European Multicentre Bronchi-
ectasis Audit and Research Collaboration (EMBARC)
stresses the importance of large cohort studies to better
understand the varying aetiologies that drive the disease
across different populations. Elucidating differences in
less studied organisms including fungi and viruses are
also highlighted and research focus in these key areas
would improve our understanding of disease while per-
mitting a more personalised therapeutic approach per-
haps varied by geographic region [121].
Differences in the aetiology, epidemiology and micro-
biology of bronchiectasis can be observed across coun-
tries and continents and may influence the observed
clinical phenotypes, which in turn likely influences treat-
ment and outcomes. Studies targeting geographic re-
gions where a paucity of data exists including Asia,
Africa and South America are now necessary. If effective
treatment approaches are to be realised in bronchiectasis
– a condition for which no licenced therapies currently
exist – success will likely depend on more targeted ap-
proaches that acknowledge the marked geographic vari-
ability associated with this heterogeneous disease.
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